• Detailed analysis of the dose

  2024-11-14

  

  Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory

• It has been reported that trehalose shows beneficial effects

  2024-11-14

  

  It has been reported that trehalose shows beneficial effects in a mouse model of several neurodegenerative diseases [21], [22], [23]. There are also reports showing that trehalose can improve the impaired cognitive and learning ability and reduced Aβ deposit in hippocampus of APP/PS1 transgenic mice

• PF is orally bioavailable and has appropriate

  2024-11-14

  

  PF-06409577 is orally bioavailable and has appropriate pharmacokinetic properties for use in rodents, allowing us to evaluate its impact on lipid and cholesterol biosynthesis in vivo (Cameron et al., 2016). PF-06409577 lowered the incorporation of 14C-acetate into hepatic lipids in vivo in a dose de

• br Stress glucocorticoids as risk factor for

  2024-11-13

  

  Stress/glucocorticoids as risk factor for Alzheimer’s Disease: preclinical studies A role for glucocorticoids in shaping the risk for AD is supported by animal studies using rats or mice injected with Aβ oligomers, tau protein or excitotoxins, or transgenic (Tg) mice carrying mutations associated

• Our results add to previously published data

  2024-11-13

  

  Our results add to previously published data on the contribution of ALDH3A1 to the optical properties of the cornea. Specifically, the study by Nees et al. (2002) was among the first to examine whether ALDH3A1 serves as a structural component in the cornea and similarly to lens crystallins. Their ex

• hydroxydopamine OHDA is a selective catecholaminergic neurot

  2024-11-13

  

  6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and

• Application of the broad acting HTR antagonist methiothepin

  2024-11-13

  

  Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L

• where is the breaking force In

  2024-11-13

  

  where is the breaking force. In the following, the details of the simulation are presented and subsequently, the results are discussed. The initial atomic structure is extracted from the crystal structure of single AF (PDB identification 3G37) which consist 12 monomers. As aforementioned 4 monomer

• The observation that vortioxetine blocks HT

  2024-11-13

  

  The observation that vortioxetine blocks 5-HT-induced currents in 5-HT3 receptor-expressing oocytes suggests that vortioxetine acts to functionally antagonize these receptors, and is in line with previously published data (Bang-Andersen et al., 2011). For example, Mørk et al. (2012) demonstrated tha

• In order to increase the oral bioavailability abiraterone is

  2024-11-13

  

  In order to increase the oral bioavailability, abiraterone (157) is being used in the form of its 3β-acetoxy prodrug, abiraterone acetate (156). In spite of the fact that high-fat meals increase the oral PSB 1115 of abiraterone acetate (156), it is recommended that this drug should be taken on an em

• Previously several genes such as cytokine Lyu and

  2024-11-13

  

  Previously, several genes such as cytokine (Lyu and Park, 2007), cell motility-associated genes (Schotterl et al., 2017), transforming growth factor-β (TGF-β), TGF-β receptor II which is a cell surface receptor with serine/threonine kinase activity (Jiang et al., 2014, Schotterl et al., 2017), cell

• AT-101 In conclusion AXL overexpression preexisted in a

  2024-11-13

  

  In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi

• In addition to the data provided by the

  2024-11-13

  

  In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr

• Aurora A overexpression is also related to the activation

  2024-11-13

  

  Aurora-A overexpression is also related to the activation of NF-κB, a potent anti-apoptotic effector that may play a role in preventing apoptosis in cancer Mevastatin [18]. These data show that we are still at the beginning of unraveling the complex mechanism by which these gene products and protei

• DY131 receptor Demonstration of in vivo efficacy of potentia

  2024-11-13

  

  Demonstration of in vivo efficacy of potential chemopreventive agents in animal models is necessary for their clinical development. Our present study provides experimental evidence that CuB 0.1μmol by oral administration (for 2weeks before the cancer cell injection, 5days per week) significantly inh

16719 records 63/1115 page Previous Next First page 上5页 6162636465 下5页 Last page